Cargando…

P1572: COVID-19 MORTALITY IN HIGH-RISK PATIENTS AFTER ALLO-HSCT AND CAR-T: IMPROVED OUTCOME THROUGH A PANDEMIC.

Detalles Bibliográficos
Autores principales:	Sannipoli, Daniele, Camilla, Gariazzo, Farina, Francesca, Diral, Elisa, Bruno, Alessandro, Clerici, Daniela, Marktel, Sarah, Canziani, Luca, Catalano, Gloria, Fiore, Paolo, Oltolini, Chiara, Querini, Patrizia Rovere, Corti, Consuelo, Ciceri, Fabio, Vitali, Giordano, Lupo-Stanghellini, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430049/ http://dx.doi.org/10.1097/01.HS9.0000973164.50042.3f

Ejemplares similares

PB2575: HIGH INCIDENCE OF RESPIRATORY TRACT INFECTIONS FOLLOWING COVID-19 WAVES IN PATIENTS WITH PLASMA CELL DYSCRASIAS
por: Farina, Francesca, et al.
Publicado: (2023)

P1549: HIGH PREVALENCE OF RESPIRATORY SYNCYTIAL VIRUS IN HAEMATOLOGICAL PATIENTS AFTER COVID19 WAVES.
por: Farina, Francesca, et al.
Publicado: (2023)

Case Report: Invasive Fungal Infection and Daratumumab: A Case Series and Review of Literature
por: Farina, Francesca, et al.
Publicado: (2022)

PB2426: SORAFENIB MAINTENANCE TAILORED TO FLT3-MUTATED AML AFTER ALLOGENEIC HCT IS HIGHLY FEASIBLE AND EFFECTIVE: A REAL-LIFE EXPERIENCE
por: Diral, Elisa, et al.
Publicado: (2023)

PB2208: CAR-T TREATMENT POST FIRST ALLO-HSCT FAILURE MAY HAVE DIFFERENT PROCESSION COMPARING TO CAR-T BEFORE ALLO-HSCT
por: wang, D., et al.
Publicado: (2022)

Breakthrough Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplantation
por: Liberatore, Carmine, et al.
Publicado: (2021)

Following-up allogeneic transplantation recipients during the COVID-19 pandemic
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2020)

Lung Ultrasound to Evaluate Invasive Fungal Diseases after Allogeneic Hematopoietic Stem Cell Transplantation
por: Raffaella, Greco, et al.
Publicado: (2019)

Second Solid Cancers After Hematopoietic Stem Cell Transplantation: Active Surveillance During Long-term Follow-up
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Impact of tixagevimab/cilgavimab prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplants and CAR T-cell therapy: a single center experience.
por: Xue, Elisabetta, et al.
Publicado: (2023)

1559. Hematopoietic Cell Transplantation with Post-transplant Cyclophosphamide: Impact of Donor Type on Pre-engraftment Blood-Stream Infections
por: Oltolini, Chiara, et al.
Publicado: (2018)

COVID-19 in recipients of allogeneic stem cell transplantation: favorable outcome
por: Lupo-Stanghellini, Maria Teresa, et al.
Publicado: (2021)

Minnesota acute graft-versus-host disease risk score predicts survival at onset of graft-versus-host disease after post-transplant cyclophosphamide prophylaxis
por: Ardizzoia, Federica, et al.
Publicado: (2022)

Family caregivers’ support needs during allo-HSCT—a longitudinal study
por: Kisch, Annika M., et al.
Publicado: (2020)

Cytokine Overproduction and Immune System Dysregulation in alloHSCT and COVID-19 Patients
por: Lange, Andrzej, et al.
Publicado: (2021)

PB2441: CD34+ CELL DOSE EFFECTS ON CLINICAL OUTCOMES OF ALLO-HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT)
por: Zhou, Shengnan, et al.
Publicado: (2023)

Defibrotide Prophylaxis of Sinusoidal Obstruction Syndrome in Adults Treated With Inotuzumab Ozogamicin Prior to Hematopoietic Stem Cell Transplantation
por: Giglio, Fabio, et al.
Publicado: (2022)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

Allogeneic CAR-T bridging to allo-HSCT as a treatment strategy for refractory adult Burkitt’s lymphoma: a case report
por: Cheng, Ling, et al.
Publicado: (2022)

Polymyositis as a manifestation of chronic graft‐versus‐host disease after allo‐HSCT
por: Meng, Lijuan, et al.
Publicado: (2018)

Targeting SLP76:ITK interaction separates GVHD from GVL in allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2021)

CAR-T bridging to allo-HSCT as a treatment strategy for relapsed adult acute B-lymphoblastic leukemia: a case report
por: Wen, Shupeng, et al.
Publicado: (2018)

Desialylation is associated with apoptosis and phagocytosis of platelets in patients with prolonged isolated thrombocytopenia after allo-HSCT
por: Zhang, Xiao-Hui, et al.
Publicado: (2015)

Targeting Interleukin-2-Inducible T-Cell Kinase (ITK) Differentiates GVL and GVHD in Allo-HSCT
por: Mammadli, Mahinbanu, et al.
Publicado: (2020)

Development of a Nomogram for Predicting the Cumulative Incidence of Disease Recurrence of AML After Allo-HSCT
por: Zhang, Tongtong, et al.
Publicado: (2021)

Treatment options for adult intermediate-risk AML patients in CR1: Allo-HSCT or chemotherapy?
por: Wang, Luxiang, et al.
Publicado: (2023)

A nomogram model for predicting ocular GVHD following allo-HSCT based on risk factors
por: Wang, Wen-hui, et al.
Publicado: (2023)

Allo-HSCT compared with immunosuppressive therapy for acquired aplastic anemia: a system review and meta-analysis
por: Zhu, Yangmin, et al.
Publicado: (2020)

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2020)

A Nationwide Study of GATA2 Deficiency in Norway—the Majority of Patients Have Undergone Allo-HSCT
por: Jørgensen, Silje F., et al.
Publicado: (2021)

P1326: FACTORS ASSOCIATED WITH THE OUTCOME OF ALLO-HSCT FOR ADVERSE-CYTOGENETIC RISK ACUTE MYELOID LEUKEMIA
por: Cerezo-Martin, J. M., et al.
Publicado: (2022)

Clinical study of late-onset hemorrhagic cystitis after allo-HSCT without in vitro T-cell depletion
por: Yuan, Hailong, et al.
Publicado: (2022)

Outcomes of Second Anti-CD19 CAR T-Cell Therapy (CART2) in Acute B Lymphoblastic Leukemia and the Impact of Allo-HSCT on Efficacy
por: Xu, Qianwen, et al.
Publicado: (2023)

Minimal residual disease detection by next-generation sequencing in multiple myeloma: Promise and challenges for response-adapted therapy
por: Ferla, Valeria, et al.
Publicado: (2022)

Allo-HSCT recipients with invasive fungal disease and ongoing immunosuppression have a high risk for developing tuberculosis
por: Yang, Apeng, et al.
Publicado: (2019)

Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study
por: Willasch, Andre Manfred, et al.
Publicado: (2021)

Pre-transplant Rehabilitation to Decrease the Post-transplant Length of Stay for Hematological Malignancy Patients Undergoing Allo-HSCT
por: Matsugaki, Ryutaro, et al.
Publicado: (2021)

Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT
por: Chen, Zhangjie, et al.
Publicado: (2023)

Letermovir reduces chronic GVHD risk in calcineurin inhibitor-free GVHD prophylaxis after hematopoietic cell transplantation
por: Lorentino, Francesca, et al.
Publicado: (2022)

Las visitas pastorales de Mazapil 1572-1856
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_4nsck52d65crqu4cn9sjrslq6e